Enanta Pharmaceuticals to Host Conference Call on May 6 at 4:30 p.m. ET to Discuss its Financial Results for its Fiscal Second Quarter Ended March 31, 2024
April 29 2024 - 7:00AM
Business Wire
Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage
biotechnology company dedicated to creating small molecule drugs
for virology and immunology indications, today announced that it
plans to report its financial results for its fiscal second quarter
ended March 31, 2024, after the U.S. market closes on May 6, 2024.
Enanta management will host a conference call at 4:30 p.m. ET to
discuss these results and provide an update on Enanta’s business,
including its research and development pipeline.
Conference Call and Webcast Information
The live webcast can be accessed under "Events &
Presentations" in the investors section of Enanta’s website. To
join by phone, participants can register for the call here. It is
recommended that participants register a day in advance or at a
minimum of 15 minutes before the call. Once registered,
participants will receive an email with the dial-in information.
The archived webcast will be available on Enanta’s website for
approximately 30 days following the event.
About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug
discovery capabilities to become a leader in the discovery and
development of small molecule drugs for virology and immunology
indications. Enanta’s research and development programs are
currently focused on respiratory syncytial virus (RSV) and chronic
spontaneous urticaria (CSU) and the company has previously advanced
clinical-stage compounds for SARS-CoV-2 (COVID-19) and chronic
hepatitis B virus (HBV) infection.
Glecaprevir, a protease inhibitor discovered by Enanta, is part
of one of the leading treatment regimens for curing chronic
hepatitis C virus infection (HCV) and is sold by AbbVie in numerous
countries under the trade names MAVYRET®(U.S.) and
MAVIRET®(ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta’s
royalties from HCV products developed under its collaboration with
AbbVie contribute ongoing funding to Enanta’s operations. Please
visit http://www.enanta.com for more information.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240429947262/en/
Media and Investors Contact Jennifer Viera
jviera@enanta.com
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From Apr 2024 to May 2024
Enanta Pharmaceuticals (NASDAQ:ENTA)
Historical Stock Chart
From May 2023 to May 2024